Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity-Reference-Cited by-同舟云学术

Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity

Published:2015-08-26 Issue:17 Volume:58 Page:7057-7075
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hennessy Edward J.¹,Oza Vibha¹,Adam Ammar¹,Byth Kate¹,Castriotta Lillian¹,Grewal Gurmit¹,Hamilton Geraldine A.¹,Kamhi Victor M.¹,Lewis Paula¹,Li Danyang¹,Lyne Paul¹,Öster Linda²,Rooney Michael T.¹,Saeh Jamal C.¹,Sha Li¹,Su Qibin¹,Wen Shengua¹,Xue Yafeng²,Yang Bin¹

Affiliation:

1. Oncology iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

2. Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca R&D Mölndal, S-43183, Mölndal, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01078

Reference45 articles.

1. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology

2. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720